PubMed HealthSearch

PubMed · 8531122

Acetaminophen does not decrease hepatic 3'-phosphoadenosine 5'-phosphosulfate in mice.

Abstract

Capacity-limited sulfation of chemicals is thought to be due to the limited availability of 3'-phosphoadenosine 5'-phosphosulfate (PAPS), the cosubstrate for sulfation, which in turn is limited by the availability of its precursor, inorganic sulfate. Because this concept evolved from experimental data obtained from rats, and species differences have also been reported on acetaminophen (AA) sulfation, this study examined the effects of AA on PAPS and sulfate concentrations in mice, another widely used experimental animal. AA lowered serum and liver sulfate concentrations approximately 50% in mice. However, contrary to observations in rats, AA (0-600 mg/kg i.p.) did not decrease hepatic PAPS concentrations in mice. In summary, these studies demonstrate that AA decreases serum and liver sulfate concentrations, but does not decrease hepatic PAPS concentrations in mice. These data indicate that 1) hepatic sulfation of high dosages of AA in mice is not limited by the availability of PAPS, and 2) there are significant species differences in the regulation of AA sulfation between rats and mice.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H J Kim, P Rozman, C D Klaassen. 1995. Acetaminophen does not decrease hepatic 3'-phosphoadenosine 5'-phosphosulfate in mice.. https://pubmed.ncbi.nlm.nih.gov/8531122/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Acetaminophen and other risk factors for excessive warfarin anticoagulation.

CONTEXT: Warfarin is highly effective in preventing thromboembolism, but increases the risk of hemorrhage, particularly at an international normalized ratio (INR) greater than 4.0. Identifying causes of excessive anticoagulation in clinical practice could help target patients at risk for elevated INRs. OBJECTIVE: To determine causes of INRs greater than 6.0 in a clinical practice setting. DESIGN: Case-control study. SETTING: Outpatient anticoagulant therapy unit. PATIENTS: Outpatients followed up prospectively from April 1995 to March 1996 who had been taking warfarin for more than 1 month, had a target INR of 2.0 to 3.0, and were able to be interviewed within 24 hours of their reported INR. Case patients had INRs greater than 6.0; controls were randomly selected from patients having INRs between 1.7 and 3.3. MAIN OUTCOME MEASURES: Factors associated with INRs greater than 6.0, including medication use, recent diet, illness, alcohol consumption, and actual warfarin use. RESULTS: A total of 93 cases and 196 controls were interviewed; they did not differ in age, indication for warfarin, length of therapy, warfarin dose, number of prescription medications, or previous INR or long-term INR variability. Acetaminophen ingestion was independently associated in a dose-dependent manner with having an INR greater than 6.0 (P for trend <.001). For the highest-dose category of acetaminophen intake, 9100 mg/wk or more, the odds of having an INR greater than 6.0 were increased 10-fold (95% confidence interval [CI], 2.6-37.9). Other factors independently associated with an INR greater than 6.0 were new medication known to potentiate warfarin (odds ratio [OR], 8.5; 95% CI, 2.9-24.7), advanced malignancy (OR, 16.4; 95% CI, 2.4-111.0), recent diarrheal illness (OR, 3.5; 95% CI,1.4-8.6), decreased oral intake (OR, 3.6; 95% CI, 1.3-9.7), and taking more warfarin than prescribed (OR, 8.1; 95% CI, 2.2-30.0). Higher vitamin K intake (OR, 0.7; 95% CI, 0.5-0.9) and habitual alcohol consumption of from 1 drink every other day to 2 drinks a day (OR, 0.2; 95% CI, 0.1-0.7) were associated with decreased risk. CONCLUSIONS: These data suggest that acetaminophen is an underrecognized cause of overanticoagulation in the outpatient setting. Several other clinically important risk factors were identified. Increased monitoring of INR values when such risk factors are present or modification of the risk factors themselves should reduce the frequency of dangerously high levels of anticoagulation.

Acetaminophen